Tie-up with Eisai Co., Ltd.
Anaeropharma Science, Inc. and Eisai Co., Ltd. have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.
Subscribe RSS